Mariner’s ImmunityBio IBRX Stock Holding History

Mariner’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-43,374	Closed	-$333K	–	3719
2026 Q1	$333K	Buy	43,374 +25,560	+143%	+$175K	﹤0.01%	2777
2025 Q4	$35.3K	Buy	17,814 +1,689	+10%	+$3.83K	﹤0.01%	3447
2025 Q3	$39.7K	Sell	16,125 -15,184	-48%	-$39.1K	﹤0.01%	3473
2025 Q2	$82.7K	Sell	31,309 -15,287	-33%	-$41.1K	﹤0.01%	3275
2025 Q1	$140K	Buy	+46,596	New	+$141K	﹤0.01%	3116

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mariner's IBRX Position: Q2 2026 in Review

Mariner sold out of ImmunityBio (IBRX) in Q2 2026, closing a stake of 43,374 shares — an estimated $333K sold.

Mariner first reported a position in IBRX in Q1 2025 and held it in 5 quarters. The position peaked at $333K in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Mariner reported no remaining ImmunityBio position as of Q2 2026 after selling out during the quarter.
Mariner sold 43,374 ImmunityBio shares in Q2 2026, an estimated $333K.
Mariner first reported a position in ImmunityBio in Q1 2025 and held it in 5 quarters.
Mariner's ImmunityBio position peaked at $333K in Q1 2026.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.